KKR sells Nordic Bioscience stake back to founder

KKR has finalized the sale of its 10% minority stake in Nordic Bioscience to the company's founder, Claus Christiansen. The investment was made by KKR in 2021 through its Health Care Strategic Growth strategy, which supported Nordic Bioscience in expanding its biomarker capabilities and strengthening its position in R&D services, clinical diagnostics, and drug development.

KKR Partner and Head of Healthcare Private Equity and Healthcare Strategic Growth teams, Kugan Sathiyanandarajah, expressed pride in collaborating with Christiansen and the Nordic Bioscience team over the past five years. Sathiyanandarajah will continue to sit on Nordic Bioscience's Board of Directors until the next ordinary general meeting, while Håkan Björklund, the current Chair, has decided to relinquish his position.

Christiansen praised KKR's strategic partnership, noting that the company has doubled its revenue and increased profitability since 2021 while continuing to strengthen its position in biomarker development.